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Fluorescence resonance energy transfer
XIAP
Caspaseosis-protein (XIAP) is the most potent intracellular inhibitor of caspases-9, -3
and -7. While highly elevated XIAP levels reduce the apoptotic response to various stimuli, the potency of
physiological XIAP expression to control caspase activation and the consequences of XIAP deﬁciency on
apoptosis execution remain controversial. We therefore analyzed parental and XIAP-deﬁcient DLD-1 and
HCT-116 colon cancer cells by employing ﬂuorescence-based single-cell imaging of mitochondrial
permeabilisation and effector caspase activation. Our results demonstrate that physiological XIAP
expression maintains a transient “off”-state for effector caspase activation following mitochondrial
permeabilisation. Loss of XIAP expression instead accelerated the caspase activation response, but did not
enhance the measured caspase activity. Apoptosis execution kinetics were independent of activating the
intrinsic or extrinsic pathway by either staurosporine or TRAIL, and corresponded to computational
systems analyses of caspase activation dynamics. We conﬁrmed a protective role of XIAP upstream
of mitochondrial permeabilisation during TRAIL-induced apoptosis, however, once mitochondria
permeabilised ultimately no cell could escape effector caspase activation, regardless of potential cell-to-
cell variability within the populations or the presence of XIAP. Our study provides comprehensive kinetic
and mechanistic insight into the rapid molecular dynamics during apoptosis execution in the presence or
absence of physiological XIAP expression.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Apoptosis is an evolutionary conserved cell death mechanism
crucial for both tissue homeostasis and the removal of superﬂuous or
damaged cells from the body of multicellular organisms. Unbalanced
apoptotic signaling can contribute to developmental defects, auto-
immune diseases, cancer, and neurological disorders. Apoptosis can be
induced via the extrinsic pathway, which is triggered by ligands
binding to their cognate death receptors, or via the intrinsic pathway
that is triggered by intracellular stress and damage such as genotoxic
drugs, inhibition of cell survival signaling, or radiation [1]. Both
pathways converge at the level of mitochondria where the balance
between pro- and antiapoptotic members of the Bcl-2 protein family
regulate the formation of pores in the outer mitochondrial membraneand Medical Physics, Royal
, Ireland. Fax: +353 1 402 2447.
l rights reserved.[2]. This mitochondrial outer membrane permeabilisation (MOMP)
facilitates the release of mitochondrial intermembrane proteins into
the cytosol, amongst them cytochrome-c (cyt-c) and Smac/Diablo [3–
5]. Single-cell imaging studies using green ﬂuorescent protein (GFP)-
based fusion proteins demonstrated that the synchronous release of
cyt-c and Smac proceeds with rapid kinetics and is accompanied by
mitochondrial depolarisation due to impaired respiration after onset
of MOMP [6–9].
In the presence of dATP/ATP, cytosolic cyt-c induces the oligomer-
isation of apoptotic protease activation factor 1 (Apaf-1) and pro-
caspase-9 into the megadalton apoptosome complex that facilitates
caspase-9 activation [10]. Caspase-9 in turn activates effector
caspases-3 and -7 which are responsible for most of the morpholo-
gical and biochemical changes that characterize apoptosis [11]. The X-
linked-inhibitor-of-apoptosis-protein (XIAP) is the most effective and
best characterized intracellular inhibitor of caspase activity and
directly inhibits initiator caspase-9, as well as effector caspases-3
and -7 [12,13]. Following MOMP, cytosolic Smac can antagonize XIAP
by displacing caspases-3, -7 and -9 from their XIAP binding sites
[14,15]. Numerous reports described the protective role of XIAP in
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overexpression scenarios [13,16,17], and biopsies from cancer patients
point to a direct correlation between elevated XIAP expression and the
malignancy of individual tumors [18–20].
In contrast, the role of physiological XIAP expression for apoptosis
execution is still a matter of debate. XIAP-deﬁcient mice develop
normally and apoptosis induction apparently occurs normal in
response to extrinsic and intrinsic stimuli [21]. However, in colorectal,
breast and pancreatic cancer cells loss of XIAP or reduced XIAP
expression was reported to sensitize to TRAIL and CD95-induced
apoptosis [17,22,23] and was found to correlate with disturbed
lymphocyte homeostasis in humans [24]. In this study we therefore
aimed to decipher the inﬂuence of endogenous XIAP levels in DLD-1
and HCT-116 colon cancer cells on the real-time signaling dynamics of
caspase activation during apoptosis execution in living cells by
employing a combination of single-cell imaging, mathematical
systems modeling, and population studies.
2. Materials and methods
2.1. Materials
Embryo-tested mineral oil, carbonyl cyanide p-triﬂuoromethox-
yphenylhydrazone (FCCP), and cycloheximide (CHX)were fromSigma-
Aldrich (Tallaght, Dublin, Ireland). TMRM was from MobiTec (Göttin-
gen). Staurosporine (STS) was from Alexis (San Diego, CA, USA). TRAIL
was from Leinco Technologies (St. Louis, Missouri, USA). The broad
spectrum caspase inhibitor z-Val-Ala-Asp(O-methyl)-ﬂuoromethyl
ketone (z-VAD-fmk) was purchased from Bachem (St Helen's, UK).
G418 was from Invitrogen (Paisley, UK).
2.2. Cell culture and transfection
Cells were cultured in RPMI 1640 medium supplemented with
penicillin (100 μg/ml), streptomycin (100 μg/ml) and 10% fetal calf
serum (Sigma-Aldrich). Cells were transfected with 1 μg of plasmid
DNA, and 4 μl Lipofectamine 2000 (Invitrogen) per ml of serum-free
medium at 37 °C for 4 h.
2.3. Preparation of whole cell extracts and Western blotting
Cells were collected at 1000 rpm for 3 min and washed with
phosphate-buffered saline (PBS). The cell pellet was re-suspended in
lysis buffer (62.5mMTris–HCl, pH 6.8,10% (v/v) glycerin, 2% (w/v) SDS,
1 mM phenylmethylsulfonyl ﬂuoride, 1 μg/ml pepstatin A, 1 μg/ml
leupeptin, and 5 μg/ml aprotinin). Cell homogenates were centrifuged
at 15,000 ×g and 4 °C for 15 min. Protein content was determined with
the Pierce Micro-BCA Protein Assay (Pierce, Northumberland, UK). An
equal amount of protein (20 μg) was loaded onto SDS-polyacrylamide
gels. Proteins were separated at 100 V for 2.5 h and then blotted to
nitrocellulose membranes (Protean BA 83; 2 μm; Schleicher and
Schuell, Dassel, Germany) in transfer buffer (25 mM Tris, 192 mM
glycine, 20%methanol (v/v) and 0.01% SDS) at 18 V for 60min. The blots
were blocked with 5% non-fat dry milk in TBST (15 mM Tris–HCl, pH
7.5, 200 mM NaCl, and 0.1% Tween 20) at room temperature for 1 h.
Membranes were incubated with the following antibodies: a rabbit
polyclonal caspase-3 antibody (Cell Signaling Technology, Danvers,
MA, USA); a rabbit polyclonal caspase-7 antibody (Cell Signaling
Technology, USA); a mouse monoclonal XIAP antibody (H62120, clone
48, BD Transduction Laboratories, CA, USA); a rabbit polyclonal
caspase-9 antibody (218794, Calbiochem, Merck, Darmstadt, Ger-
many); mouse monoclonal cyt-c antibody (H556433, clone 7H8.2C12,
BD Biosciences); a rabbit polyclonal Smac antibody (AF-789, R and D
Systems, Minneapolis, USA); a rabbit polyclonal Apaf-1 antibody
(AB16941, Chemicon, Hampshire, UK) a goat polyclonal cIAP-1 anti-
body (AF8181, R and D Systems); a rabbit polyclonal cIAP-2 antibody(sc-7944, Santa Cruz Biotechnology); a mouse monoclonal GFP
antibody (Clontech Laboratories, Palo Alto, CA); a rabbit polyclonal
DR4 antibody (ab8414, Abcam, Cambridge, UK); a mouse monoclonal
DR5 antibody (MAB6311, clone 71908, R and D Systems); a mouse
monoclonal FADD antibody (610399, clone 1, BD Biosciences); amouse
monoclonal caspase-8 antibody (ALX-804-242, clone 125F, Axxora,
Nottingham, UK), a mouse monoclonal c-Flip antibody (ALX-840-601,
clone NF6, Axxora, Nottingham, UK); a goat polyclonal Bid antibody
(AF860, R and D Systems), a mouse monoclonal β-actin antibody
(Sigma-Aldrich). Membranes were washed with TBST three times for
5 min and incubated with anti-mouse or anti-rabbit peroxidase-
conjugated secondary antibodies (Jackson Laboratories, PA, USA) for
1 h. Blots were washed and developed using the enhanced chemilu-
minescence detection reagent (AmershamBiosciences, Buckingham-
shire, UK). Membranes were stripped in 200 mM NaOH for half an
hour, washed twice in TBST for 10 min and reprobed.
2.4. Clonogenic survival
Cells were plated and treated with the indicated concentrations of
STS for 16 h or TRAIL/CHX for 4 h. 103 treated cells were then re-plated
in fresh medium into 60 mm dishes for an additional 10 days. Colony
formation was quantiﬁed after staining with methylene blue (Sigma-
Aldrich). Untreated controls were normalized to 100% clonogenicity.
2.5. Epiﬂuorescence microscopy and digital imaging
Cells were cultivated on 35 mm glass-bottom dishes (Willco BV,
Amsterdam, The Netherlands) in 2ml of medium for at least overnight
to let them attach ﬁrmly. Cells were equilibrated with 30 nM TMRM in
RPMI 1640 medium (Sigma-Aldrich) supplemented with penicillin
(100 U/ml), streptomycin (100 μg/ml) and 10% fetal calf serum,
buffered with N-2-hydroxyl piperazine-N-2-ethane sulfonic acid
(HEPES, 10 mM; pH 7.4), covered with mineral oil, and placed in a
heated (37 °C) incubation chamber that was mounted on the
microscope stage. Cells treated with 1 μM STS were preincubated for
4 h with the drug before starting timelapse imaging. Cells induced
with 100 ng/ml TRAIL plus 1 μg/ml CHXwere treated directly on stage.
Fluorescence was observed using an Axiovert 200 M inverted
microscope equipped with a 63×1.4 NA objective (Carl Zeiss,
Germany), polychroic mirror and ﬁlter wheels in the excitation and
emission light path containing the appropriate ﬁlter sets (CFP,
excitation 436±10 nm, emission 480±20 nm; YFP, excitation 500
±10 nm, emission 535±15 nm; FRET, excitation 436±10 nm, emission
535±30 nm; dichroic mirrors for CFP, YFP and TMRM, Semrock,
Rochester, NY, USA). Images were recorded using a back illuminated,
cooled EM CCD camera (Andor Ixon BV 887-DCS). The imaging setup
was controlled by MetaMorph software (Molecular Devices, UK).
2.6. Mitochondrial membrane potential (ΔΨM) and FRET disruption
For analysis of ΔΨM kinetics in single cells, the ﬂuorescent
mitochondrial signal was segmented from the cytoplasmic and nuclear
background and the average ﬂuorescence intensity per pixel was
calculated. Onset of mitochondrial depolarization was deﬁned as the
point in time when the TMRM signal dropped irreversibly below the
initial baseline value. Caspase activation kinetics were detected at the
single-cell level by FRET analysis [25]. Images were processed using
MetaMorphsoftware (Universal Imaging, PA,USA). CFP/YFPandFRET/YFP
emission ratio traces were obtained by dividing the average ﬂuorescence
intensity values of single cells after background subtraction.
2.7. Flow cytometry
Flow cytometry was performed on a Partec Cyﬂow ML16 ﬂow
cytometer (Partec, Münster, Germany) equipped with a 488 nm
Fig. 1. Loss of XIAP expression does not result in compensatory regulation of other
proteins involved in cell death execution. (A,B) Western blot analysis of parental and
XIAP-deﬁcient HCT-116 and DLD-1 cells. (A) The expression of XIAP, Apaf-1, Caspases-9,
-3 and -7, Smac and cyt-cwas analyzed in whole cell protein extracts. β-actin served as
loading control. Asterisk indicates an unspeciﬁc signal of the XIAP antibody. (B) Whole
cell protein extracts were probed for the expression levels of cIAP-1 and cIAP-2. β-actin
served as loading control.
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cells were re-suspended in ice-cold PBS and 104 gated events were
acquired for each sample. For ΔΨM measurements cells were
incubated in 90 nM TMRM for 1 h at 37 °C prior to sample
preparation. TMRM was excited with the 488 nm laser and
ﬂuorescence emission was collected through a 590 band pass ﬁlter.
For FRET measurements, CFP was excited with the 405 nm laser and
detected through the 455 nm band pass ﬁlter. YFP was excited via
the 488 nm laser and collected through a 520 nm band pass ﬁlter.
Resonance Energy Transfer between CFP and YFP was collected
through the 520 band pass ﬁlter upon CFP excitation. Data
acquisition and analysis were performed using the Partec Flow
Max software.
2.8. Mathematical modeling of apoptosis execution
Numerical calculations were performed using a MATLAB-based
analysis script. A full documentation and experimental veriﬁcation of
the validity of this modeling tool was published before [16]. The
script is based on a set of ordinary differential equations (ODEs)
representing a reaction network of 53 reactions and 19 reaction
partners. ODEs were solved by an adaptive step Runge–Kutta method
(Gear74). The reaction network is initiated by cyt-c-dependent
apoptosome formation and mitochondrial Smac release. The model
then calculates the temporal proﬁles of all proteins and protein
complexes involved in the signaling network as well as the cleavage
proﬁles for a CFP-DEVD-YFP FRET substrate. We adapted this modelto analyze the consequences of XIAP deﬁciency on intracellular
signaling dynamics during apoptosis execution.
2.9. Statistics
Datawere tested for normality and given as means±SD or SEM. For
statistical comparison Student's t test or ANOVA and subsequent
Tukey test were used. P values smaller than 0.05 were considered to
be statistically signiﬁcant.
3. Results
3.1. No compensatory change in protein expression upon loss of XIAP in
DLD-1 or HCT-116 cells
In this study we used wild-type and XIAP-deﬁcient DLD-1 and
HCT-116 colon cancer cells generated by a gene targeting approach
disrupting the xiap locus [22] as model systems. While HCT-116
express functional p53, in DLD-1 cells both p53 alleles are mutated.
First, we tested whether loss of XIAP had any consequence on the
expression levels of key proteins involved in apoptosis execution.
Expression of Apaf-1, caspase-9, caspase-3, caspase-7, Smac and cyt-c
remained unchanged upon loss of XIAP expression as shown by
Western blotting (Fig. 1A). Previously it has been reported that XIAP
deﬁciency in mice can potentially be compensated by upregulation of
cIAP-1 and -2, two related members of the IAP family of proteins [21].
However, cIAP-1 or -2 expression levels remained unchanged in our
model systems (Fig. 1B). Taken together, our data show that the
presence or absence of XIAP expression is the only apparent
distinction in the composition of proteins involved in effector
caspase activation in DLD-1 and HCT-116 cells. We therefore conclude
that any differences in apoptotic signaling kinetics between parental
and XIAP-deﬁcient cells are attributable to XIAP.
3.2. Measurement of effector caspase activation by disruption of
ﬂuorescence resonance energy transfer (FRET)
As cells within a population do not commit to apoptotic cell death
synchronously, the real-time signaling kinetics during cell death can
only be analyzed on the level of the individual cell. To evaluate the
role of physiological XIAP expression on intracellular effector caspase
activation and activity we employed ﬂuorescence resonance energy
transfer (FRET)-based single-cell imaging. We used a recombinantly
expressed FRET probe comprised of cyan and yellow ﬂuorescent
proteins (CFP, YFP) connected by a short linker containing the
optimal recognition site (DEVD) for effector caspases-3 [25,26]. In the
intact probe the close proximity of donor (CFP) and acceptor (YFP)
allows for an efﬁcient energy transfer between the two ﬂuorophores
upon donor excitation (Fig. 2A). Cleavage of the linker disrupts the
energy transfer and results in increased CFP and decreased YFP
emission (Fig. 2B). Direct excitation of the acceptor YFP in contrast
results in stable YFP emission independent of the probe being intact
or cleaved. Therefore, by calculating CFP/YFP and FRET/YFP emission
ratios, this approach allows a ratiometric readout of the FRET
disruption kinetic. The ratiometric readout automatically corrects
for unspeciﬁc changes in ﬂuorescence intensities that affect all
channels in parallel such as slight drifts in optical focus or cellular
movements. In contrast to classical ﬂuorigenic probes, FRET mea-
surements start with a signal signiﬁcantly above the detector
sensitivity in each channel and therefore allow the measurement of
caspase activation at high signal to noise ratios.
Inducing the intrinsic apoptotic pathway in DLD-1 or HCT-116
cells by kinase inhibitor staurosporine (STS) resulted in the
processing of procaspase-3 into the active p17 and p12 subunits
(Fig. 2C). This coincided with the cleavage of the full length FRET
probe into its CFP and YFP constituents. Addition of the caspase
Fig. 2. The DEVD FRET probe is cleaved during apoptosis in DLD-1 and HCT-116 cells. (A) The effector caspase speciﬁc probe is composed of Cyan Fluorescent Protein (CFP), a linker
containing a caspase-3 speciﬁc cleavage site (DEVD), and Yellow Fluorescent Protein (YFP). Upon CFP excitation, energy is transferred from the excited CFP to the acceptor YFP by
FRET. (B) Cleavage of the linker region by effector caspase-3 results in disruption of resonance energy transfer and increased CFP emission. (C) Caspase-3 activation results in FRET
probe cleavage. Analysis of DLD-1 and HCT-116 cells expressing the DEVD FRET probe. Cells were treated with 1 μMSTS for 16 h in the presence or absence of 100 μM caspase inhibitor
z-VAD-fmk. Activation of caspase-3 and cleavage of the full length DEVD FRET probe into its CFP-DEVD and YFP constituents was sequentially analyzed inwhole cell protein extracts
byWestern blotting. The DEVD FRET probe and its cleaved fragment were detected using a GFP antibody. β-actin served as loading control. (D) CFP/YFP and FRET/YFP emission ratio
images of a representative DLD-1 cell expressing the DEVD FRET probe are shown. Following treatment with 1 μMSTS, effector caspase activation results in an increase in the CFP/YFP
and a decrease in the FRET/YFP emission ratio. Loss of TMRM ﬂuorescence indicates mitochondrial depolarization during apoptosis. Time stamp shows time after stimulus addition.
Scale bar=10 μm. (E) High resolution image of mitochondrial TMRM and cytosolic YFP ﬂuorescence in a DLD-1 cell. Scale bar=10 μm.
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FRET probe cleavage (Fig. 2C).
Using ratiometric single-cell microscopy, effector caspase activa-
tion displays as an intensity increase in CFP/YFP emission ratio
images and a concomitant intensity decrease in FRET/YFP emission
ratio images (Fig. 2D).
Tetramethyl-rhodamine-methylester (TMRM) is a sensitive ﬂuor-
escent indicator for changes in themitochondrial membrane potential
[27,28]. Loss of TMRM ﬂuorescence as an indicator for mitochondrial
depolarization is tightly coupled (≤1 min) to MOMP [6,7] and can be
measured in parallel to FRET probe cleavage (Fig. 2D). At short
exposure times and using camera binning for increased sensitivity
measurements could be performed for more than 24 h without
causing any detectable phototoxicity in control experiments.
Mitochondrial localization of TMRM ﬂuorescence and cytosolic FRETprobe signals however were clearly detectable using settings that
allow for a higher spatial resolution (Fig. 2E).
3.3. XIAP gene deletion accelerates effector caspase activation during
STS-induced apoptosis
Next, we analyzed effector caspase activity in both parental and
XIAP-deﬁcient DLD-1 cells upon inducing apoptosis via the intrinsic
pathway with 1 μM STS. FRET substrate cleavage indicated a clearly
deﬁned onset of effector caspase activation in both parental and
XIAP-deﬁcient cells, as detected by plotting CFP/YFP and FRET/YFP
emission ratios of individual cells against time (Fig. 3A and B).
Quantiﬁcations for all cells analyzed showed largely identical probe
cleavage durations of approx. 8.5 min (Fig. 3C). Similar results were
obtained when comparing parental to XIAP-deﬁcient HCT-116 cells,
Fig. 3. XIAP deﬁciency signiﬁcantly accelerates caspase activation following MOMP during STS-induced apoptosis. (A,B) CFP/YFP and FRET/YFP emission ratios of representative
parental and XIAP-deﬁcient DLD-1 cells transfected with the DEVD FRET probe and treated with 1 μM STS. Effector caspase activation results in an increase in the CFP/YFP emission
ratio and a concomitant decrease in the FRET/YFP emission ratio. Arrows indicate the onset of effector caspase activity. (C) Quantiﬁcation of effector caspase-dependent FRET
substrate cleavage. The duration of FRET probe cleavagewas quantiﬁed for all parental and XIAP-deﬁcient DLD-1 cells measured. Data aremeans (+SEM) from n=34 and 13 individual
cells from 2–3 separate experiments. No statistically signiﬁcant differences were observed between parental and XIAP-deﬁcient DLD-1 cells. (D,E) XIAP deﬁciency accelerates effector
caspase activation following MOMP. Individual traces for representative parental and XIAP-deﬁcient DLD-1 cells treated with 1 μM STS are shown. MOMP results in loss of TMRM
ﬂuorescence while effector caspase activity displays as an increase in CFP/YFP emission ratio. Arrows indicate onset of MOMP-dependent mitochondrial depolarization and effector
caspase activity, respectively. (F) Quantiﬁcation of the duration from MOMP to effector caspase activation. Statistical analysis showed that caspase activation is signiﬁcantly
accelerated in XIAP-deﬁcient DLD-1 cells. Data are means (+SEM) from 7 and 9 parental or XIAP-deﬁcient cells from 2–3 separate experiments, respectively. (G) XIAP deﬁciency does
not accelerate the onset of MOMP during STS-induced apoptosis. The time from stimulus addition to MOMP was quantiﬁed for all parental and XIAP-deﬁcient DLD-1 cells analyzed
(n=7 and 9 cells from 2–3 separate experiments, respectively). No statistically signiﬁcant differences were observed between the two groups. (H,I) Quantiﬁcation of cell death kinetics
in parental and XIAP-deﬁcient HCT-116 cells. (H) The duration of FRET substrate cleavage does not signiﬁcantly differ between parental and XIAP-deﬁcient HCT-116 cells. Data are
means (+SEM) from n=9 and 12 parental and XIAP-deﬁcient cells from 3 or 4 separate experiments respectively. (I) Caspase activation is signiﬁcantly accelerated following MOMP in
XIAP-deﬁcient HCT-116 cells. Data are means (+SEM) from n= 7 and 12 parental and XIAP-deﬁcient cells from 3–4 separate experiments.
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data indicate that during intrinsic apoptosis wild-type XIAP expres-
sion does not impair the cellular capacity to efﬁciently cleave effector
caspase substrates.
Next, FRET probe expressing cells were loaded with TMRM and
the time from MOMP to effector caspase activation was measured in
individual cells by the delay between decrease in TMRM ﬂuores-
cence and the increase in the CFP/YFP emission ratio. Comparing
parental and XIAP-deﬁcient DLD-1 cells, we noticed that XIAP-
deﬁcient cells responded faster in effector caspase activation than
parental cells following STS treatment (Fig. 3D and E). On average,
XIAP deﬁciency accelerated effector caspase activation in DLD-1 cells
by 3.2 min (Fig. 3F), which corresponded to an approx. 2.6-fold
faster response. In contrast, the time from stimulus addition until
MOMP was not affected by the loss of XIAP (Fig. 3G). We did not
detect any cells undergoing MOMP without subsequent effector
caspase activation. Similar results were obtained when comparing
parental and XIAP-deﬁcient HCT-116 cells (Fig. 3I). These data show
that in the intrinsic pathway loss of XIAP expression is sufﬁcient toaccelerate effector caspase activation following MOMP within living
cells. However, the efﬁciency of the subsequent substrate cleavage is
not signiﬁcantly enhanced.
3.4. XIAP gene deletion accelerates effector caspase activation during
TRAIL-induced apoptosis
Next, we analyzed the signaling kinetics following induction of the
TRAIL death receptor pathway in DLD-1 or HCT-116 colon cancer cells.
We furthermore investigated whether loss of XIAP expression is
sufﬁcient to promote caspase-8-induced caspase-3 activation before
MOMP sets in. TRAIL was administered in combination with CHX,
whichwas required to suppress TRAIL-induced translation-dependent
survival signaling [29,30] (Supplemental Fig. 1A). CHX alone did not
induce any detectable levels of caspase-3 activation for the duration of
the experiments (Supplemental Fig. 1B and C). Inducing apoptosis
with 25 or 100 ng/ml TRAIL plus 1 μg/ml CHX, we could not measure
any signiﬁcant differences in intracellular effector caspase activity
between individual parental and XIAP-deﬁcient DLD-1 cells as shown
Fig. 4. XIAP deﬁciency signiﬁcantly accelerates caspase activation following MOMP
during TRAIL-induced apoptosis. (A,B) Quantiﬁcation of signaling kinetics in DLD-1 cells
treated with 100 or 25 ng/ml TRAIL/1 μg/ml CHX. (A) The duration of FRET substrate
cleavage was quantiﬁed for all parental and XIAP-deﬁcient DLD-1 cells analyzed. Data
are shown as means (+SEM). n=67 and 71 parental and XIAP-deﬁcient cells were
analyzed from 4–5 separate experiments in response to 100 ng/ml TRAIL. n=16 and 18
parental and XIAP-deﬁcient cells were analyzed from 3 separate experiments each in
response to 25 ng/ml TRAIL. No statistically signiﬁcant differences were observed
between parental and XIAP-deﬁcient DLD-1 cells. (B) Quantiﬁcation of the delay
betweenMOMP and effector caspase activation. Statistical analysis showed that caspase
activation is signiﬁcantly accelerated in XIAP-deﬁcient DLD-1 cells. n=30 individual
cells from 4 separate experiments were analyzed per group in response to 100 ng/ml
TRAIL. n=13 individual cells from 3 separate experiments were analyzed per group in
response to 25 ng/ml TRAIL. Data are means (+SEM). (C,D) Quantiﬁcation of signaling
kinetics in HCT-116 cells treated with 100 ng/ml TRAIL/1 μg/ml CHX. (C) The duration of
FRET substrate cleavage was quantiﬁed for all parental and XIAP-deﬁcient HCT-116 cells
analyzed. Data aremeans (+SEM) from n=23 and 22 parental or XIAP-deﬁcient cells. No
statistically signiﬁcant differences were observed between parental and XIAP-deﬁcient
HCT-116 cells. (D) Quantiﬁcation of the delay between MOMP and effector caspase
activation. Statistical analysis showed that caspase activation is signiﬁcantly accelerated
in XIAP-deﬁcient HCT-116 cells. Data are means (+SEM) of n=22 cells per group from 2
or 3 separate experiments, respectively.
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the time between mitochondrial depolarization and effector caspase
activation (Fig. 4B), we again found that loss of XIAP expression
accelerated effector caspase activation following MOMP. No cells were
observed that underwent MOMPwithout subsequent effector caspase
activation, neither could we observe any cells showing effector
caspase activity before MOMP (n=30 cells per group analyzed).
Similar results were obtained in parental and XIAP-deﬁcient HCT-116
cells (Fig. 4C and D).
These data indicated that MOMP is the key event leading to
effector caspase activation during TRAIL-induced extrinsic apoptosis
in DLD-1 and HCT-116 cells, independent of the presence or absence of
XIAP. A direct activation of caspase-3 by caspase-8 therefore either is a
rare event in DLD-1 or HCT-116 cells, or so tightly coupled withMOMP
that we currently cannot resolve it in time (max. experimental
temporal resolution=40 s).
3.5. Systems modeling predicts an accelerated caspase-3 activation in
the absence of XIAP
As experimental approaches investigating the dynamics of
intracellular signaling networks are limited by the number of
parameters that can be observed in parallel, in recent years
mathematical systems analyses have successfully been employed to
gain a deeper understanding of the complexity of apoptotic signaling
[16,31,32]. To provide a comprehensive explanation for the observed
biological effects, we adapted a recently developed computational
model for MOMP-dependent caspase activation that allows calculat-
ing the temporal proﬁles of the proteins and protein complexes
involved in effector caspase activation [16]. It comprises the processes
from mitochondrial cyt-c and Smac release to effector caspase
activation and incorporates the biochemical characteristics of the
proteins involved. The model was originally developed to quantita-
tively predict responses in HeLa cervical cancer cells but can generate
qualitative hypotheses for other cell types as well [16].
We used the model to calculate the cleavage kinetics of effector
caspase substrates in parental and XIAP-deﬁcient cells. The cleavage
kinetics resembled the experimental traces obtained: XIAP-deﬁcient
cells were calculated to have a dramatically reduced delay between
onset of cyt-c release and onset of substrate cleavage that normally
occurs in parental cells (Fig. 5A and B). Independent of the presence or
absence of XIAP, the model also suggests that once caspase-3 is
activated, the intracellular substrate cleavage rates are largely
identical, as displayed by similar slopes of the substrate cleavage
traces (Fig. 5A and B).
We then analyzed how the loss of XIAP expression affects the
temporal proﬁles of caspases-9 and -3 (Fig. 5C and D). In parental cells
the mathematical analysis predicts that the fraction of free unbound
XIAP is rapidly consumed after the onset of cyt-c release (Fig. 5C). This
response is due to XIAP efﬁciently binding to cytosolic Smac,
apoptosome-activated caspase-9 (autocatalytically processed to the
p35/p12 subunit composition) and caspase-3 generated during the
ﬁrst 5-10 min after cyt-c release (XIAP–Smac and XIAP–caspase
complexes not shown). The XIAP inhibitory effect is calculated to be
overcome at approx. 10% remaining free XIAP, and results in a slight
increase of free caspase-9 (p35/p12). This amount seems sufﬁcient to
allow caspase-3-driven processing of caspase-9 (p35/p12) to caspase-
9 (p35/p10). As caspase-9 (p35/p10) can no longer be inhibited by
XIAP [33,34], in the simulation this leads to an enhanced caspase-3
activation (Fig. 5C).
In contrast, in XIAP-deﬁcient cells the calculated initial delays in
the caspases-9 and -3 responses are lost (Fig. 5D). Free caspase-9 (p35/
p12) is generated directly after onset of cyt-c release and in turn
produces signiﬁcant amounts of free caspase-3. The increase in
caspase-3 is no longer preceded by caspase-9 (p35/p10) generation
(Fig. 5D). The absence of XIAP consequently also results in higherpredicted amounts of free caspases-9 and -3 than in the parental cell
model (Fig. 5D).
3.6. Loss of XIAP expression sensitizes to TRAIL but not STS-induced
apoptosis
The single-cell analyses suggest that physiological XIAP expression
does not play a crucial role for cell death signaling upon activating the
intrinsic or extrinsic pathway. To investigate whether these results are
sufﬁcient to fully understand the consequences of XIAP deﬁciency on
cell survival and proliferation, we carried out clonogenic survival
assays in response to STS and TRAIL. Following treatment with high
(1 μM) or low (0.3 μM) doses of STS, parental DLD-1 cells had no
apparent long term survival or proliferation advantage over the XIAP-
Fig. 5. Computational systems analysis conﬁrms the acceleration of effector caspase-3 activation upon loss of XIAP. The model of the protein interaction network is initiated by two
input functions resembling cyt-c-induced apoptosome formation and Smac release and is based on a set of ordinary differential equations, taking into account the biochemical
characteristics of the individual proteins (see Materials and methods for details). (A,B) Mathematically predicted cleavage proﬁles of intracellular DEVD substrates by effector
caspases in parental and XIAP-deﬁcient cells. Arrows indicate the onset of substrate cleavage. Cleavage proﬁles can be compared to experimental results on DEVD FRET substrate
cleavage in single cells. (C,D) Modeled protein proﬁles of free XIAP and the uninhibited fractions of caspases-9 and -3 in parental (C) and XIAP-deﬁcient (D) cells.
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colony formation (Fig. 6A and B). In contrast, we found that upon
inducing apoptosis with various doses of TRAIL (5 to 100 ng/ml+1 μg/
ml CHX) parental DLD-1 cells had a proliferation advantage over the
XIAP-deﬁcient cell line. This proliferation advantage was more
pronounced at lower doses of TRAIL (Fig. 6C and D). Similar results
were obtained for parental or XIAP-deﬁcient HCT-116 cells (data not
shown). These results suggest that the XIAP levels in the parental DLD-
1 and HCT-116 cells conferred a protection against induction of
apoptosis with TRAIL in a subpopulation of cells which cannot be
explained by our previous ﬁndings.
Protection conferred by XIAP could be a rare event that is difﬁcult
to detect in single-cell imaging experiments due to the limited
number of cells observable by time lapsemicroscopy. To obtain single-
cell data of effector caspase activation at population scale, we
analyzed effector caspase activation by measuring FRET probe
cleavage in response to TRAIL using ﬂow cytometry. Subpopulations
with intact or cleaved FRET probe could clearly be separated in DLD-1
cells (Fig. 6E and F) and HCT-116 cells (not shown). Dose response and
time course treatment of parental and XIAP-deﬁcient DLD-1 cells
showed that parental cells indeed were signiﬁcantly protected from
TRAIL-induced FRET probe cleavage (Fig. 6G and H). As a control,
addition of caspase inhibitor z-VAD-fmk potently inhibited probe
cleavage and ensured the speciﬁcity of the read out. Similar results
were obtained for HCT-116 cells (Fig. 6I and J).
To exclude that different expression levels of proteins involved in
TRAIL induced apoptosis cause the observed sensitization of XIAP-
deﬁcient cells, we performed additional immunoblotting comparisons
(Fig. 6K). We did not detect any up- or downregulation of key
components of the TRAIL-induced DISC complex such as death
receptors 4 and 5 (DR 4, DR 5) or Fas-associated death domain
(FADD). Neitherwere caspase-8, c-Flip or Bid expression levels affected
by the loss of XIAP (Fig. 6K).3.7. TRAIL-sensitization of XIAP-deﬁcient cells is uncoupled from MOMP-
induced effector caspase activation
We next tested the hypothesis that the protective effect of XIAP
during TRAIL-induced apoptosis was due to cells escaping effector
caspase activation after MOMP. To analyze whether wild-type XIAP
expression can block apoptotic signaling following MOMP, we loaded
FRET probe expressing cells with TMRM and ﬂow cytometrically
analyzed whether cells underwent MOMP but did not cleave the FRET
probe. In neither DLD-1 nor in HCT-116 cells we detected cells that
depolarized without cleaving the DEVD FRET probe (Fig. 7A and B). As
a control, dissipating the mitochondrial membrane potential by FCCP
showed a marked increase in depolarized cells with an intact DEVD
FRET probe. These results exclude the possibility that physiological
XIAP expression or cell-to-cell variabilities within a population of cells
are capable of blocking apoptotic signaling following MOMP in DLD-1
and HCT-116 colon cancer cells and demonstrate the robustness of the
cell death decision once MOMP occurred.
4. Discussion
In the present study we found that in the living cell system loss of
XIAP expression accelerates effector caspase activation following
MOMP and also that wild-type XIAP expression in DLD-1 and HCT-116
colon cancer cells is not sufﬁcient to prevent effector caspase
activation following MOMP. The experimental ﬁndings corresponded
to mathematical systems analyses that elucidated the underlying
molecular dynamics between XIAP, caspases-9 and -3.
The molecular structure of XIAP comprises three characteristic
baculoviral IAP repeats (BIR1-3) which are followed by a terminal
RING domain. XIAP inhibits initiator caspase-9 via the BIR3 domain,
and effector caspases-3 and -7 via interaction with a region directly
preceding the BIR2 domain [35,36]. Additionally, the E3-ubiquitin
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proteolytic degradation of active caspases and Smac via the protea-
some [37,38]. Caspase activities in in vitro assays are inversely
proportional to the concentration of XIAP, with up to ~100-fold
molar excess of XIAP reported to substantially inhibit caspases-3 and -7 activities [39]. At the approximate equimolar concentrations
observed in living cells [16], the enzyme–inhibitor relationship
alone thus cannot explain the delay in effector caspase activity
observed after MOMP. The ability to transiently maintain such an
“off”-state directly arises from the topology of the signaling network.
Fig. 7. XIAP does not prevent apoptosis execution following MOMP. (A) Populations of
parental and XIAP-deﬁcient DLD-1 cells transfected with the DEVD FRET probe were
loaded with TMRM and treated for indicated times with 25 ng/ml TRAIL in the presence
of 1 μg/ml CHX. Bars show the percentage of cells that underwent MOMP but did not
cleave the DEVD FRET probe. As a positive control, mitochondria of untreated cells were
depolarized with 10 μM FCCP. The positive control also reﬂects the overall percentage of
positively transfected cells which express the FRET probe signiﬁcantly above back-
ground level in these experiments. Data aremeans+SEM from n=3 parallel cultures. (B)
As in (A), FRET probe cleavage following MOMP was analyzed for parental and XIAP-
deﬁcient HCT-116 cells. Data are means+SEM from n=3 parallel cultures.
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the activation of initiator caspase-9 is controlled by XIAP. This XIAP
block is only overcome upon sufﬁcient release of Smac and sufﬁcient
generation of caspase-9 (p35/p10) by positive feedback between
caspases-3 and -9 [33,34]. This suggests that the caspase-9 inhibitory
function of XIAP may be more potent in regulating apoptosis
execution than its caspase-3/-7 inhibitory function, which corre-
sponds to the ﬁndings of a XIAP overexpression study in NT2
teratocarcinoma cells [40]. Furthermore, it was shown that the
competition of caspases-3 and -9 for XIAP binding over time resultsFig. 6. XIAP deﬁciency sensitizes to TRAIL but not STS-induced apoptosis. (A) Loss of XIAP d
Clonogenic survival was assessed for parental and XIAP-deﬁcient DLD-1 cells treated with in
was quantiﬁed as percentage of untreated controls. Data are means+S.D. from n=3 cultures.
apoptosis. Clonogenic survival was assessed for parental and XIAP-deﬁcient DLD-1 cells treat
clonogenic survival. Survival was quantiﬁed as percentage of untreated controls. Data aremea
(E) Untreated DLD-1 cells express an intact probe as indicated by strong emission in the FRE
TRAIL/1 μg/ml CHX for 4 h the FRET probe is cleaved, as displayed by an increased CFP emis
cleaved the DEVD FRET probe. Parental and XIAP-deﬁcient DLD-1 cells were treated with th
range caspase inhibitor z-VAD was used as an additional control. Data are means+S.D. from
XIAP-deﬁcient cells. Experiments were repeated with similar results. (H) Time course analysi
ml TRAIL in the presence of 1 μg/ml CHX for up to 6 h. Co-treatment with broad range casp
parallel cultures. Asterisks indicate signiﬁcant differences between parental and XIAP-deﬁc
experiments were carried out in parental and XIAP-deﬁcient HCT-116 cells as well. Data arem
parental and XIAP-deﬁcient cells. Experiments were repeated with similar results. (K) Loss of
induced apoptosis induction. Parental and XIAP-deﬁcient HCT-116 and DLD-1 cells were ana
caspase-8, c-Flip, and Bid was analyzed in whole cell protein extracts. β-actin served as loain a redistribution of XIAP from caspase-9 to caspase-3, a process that
contributes to systems bistability and the strictness of the initiated cell
death process [16,41]. Experimentally, direct measurements of
differential caspase-9 activities in living cells currently cannot be
performed due to largely overlapping substrate speciﬁcities between
caspase-9 and effector caspases, the high catalytic activity of caspase-
3, as well as the intracellular concentrations of caspase-3 which
typically exceed the amounts of caspase-9 [16,42–44]. Our results
therefore highlight the advantage of combining real-time single-cell
and systems analyses to elucidate the mechanistic and kinetic details
of rapid and complex signaling dynamics.
Even though the “off”-state at wild-type XIAP expression in DLD-1
and HCT-116 cells is not sufﬁcient to prevent effector caspase
activation, it indicates a possible control mechanism that potentially
allows conditions where XIAP can stop signal progression and prevent
cell death. Indeed it was shown in postmitotic cardiomyocytes and
differentiated neuronal cells that if the composition of pro- and
antiapoptotic proteins in the execution network changes in favor for
XIAP, caspase activation following MOMP can be fully inhibited [45–
47]. This characteristic could also be of fundamental importance to
establish previously reported threshold requirements for cyt-c which
may allow switching off the caspase response upon accidental or
submaximal cyt-c release [48,49]. Correspondingly, human neutro-
phils expressing only trace amounts of cyt-c but still capable of
executing apoptosome-dependent apoptosis were shown to have
massively reduced XIAP levels [50]. Importantly, the swift effector
caspase response following MOMP that we detected in the absence of
XIAP furthermore also demonstrates the rapidness of apoptosome
formation within living cells for the ﬁrst time.
Interestingly, XIAP-deﬁcient mice seem to develop normally and
XIAP loss was suggested to be compensated by increased cIAP-1 and -
2 expression, indicating that XIAPmight be obsolete in mammals [21].
Yet, this ﬁnding could not be reproduced in a later study [51].
Furthermore, even though cIAP-1 and -2 can bind to caspases-9, -3
and -7 they lack the sequence speciﬁc requirement for caspase
inhibition, questioning their potential to counterbalance the loss of
XIAP [52,53].
To counterbalance the loss of XIAP [52,53]. cIAPs have been shown to
enforce their own degradation and that of their binding partners by
ubiquitination [51,54,55], and recent reports showed that IAP antago-
nists enforce cIAP degradation, leading to the induction of TNF-α
mediated apoptosis [56–58]. Importantly, this response was indepen-
dent of a caspase binding function of cIAPs. Their anti-apoptotic
potential during apoptosis execution thusmight be limited to enhancing
the turnover of active caspases and Smac rather thanhaving overlapping
functionswith XIAP.We did not observe any compensatory regulation of
cIAPs or key proteins involved in cell death execution in our model
systems, making it unlikely that other factors compensate for XIAP loss
at least in human cells. This conclusion is further supported by the
recent ﬁnding that XIAP deﬁciency in humans is associated withoes not impair clonogenic survival and proliferation following STS-induced apoptosis.
dicated concentrations of STS for 16 h. (B) Quantiﬁcation of clonogenic survival. Survival
(C) Loss of XIAP impairs clonogenic survival and proliferation following TRAIL-induced
ed with indicated concentrations of TRAIL and 1 μg/ml CHX for 4 h. (D) Quantiﬁcation of
ns+S.D. from n=3 cultures. (E,F) Flow cytometric analysis of DEVD FRET probe cleavage.
T channel and low emission in the CFP channel. (F) In DLD-1 cells treated with 25 ng/ml
sion. (G) Dose-dependent ﬂow cytometric quantiﬁcation of the percentage of cells that
e indicated concentrations of TRAIL and 1 μg/ml CHX for 4 h. Co-treatment with broad
n=3 parallel cultures. Asterisks indicate signiﬁcant differences between parental and
s of the percentage of cells cleaving the DEVD FRET probe. Cells were treated with 25 ng/
ase inhibitor z-VAD was used as an additional control. Data are means+S.D. from n=3
ient cells. Experiments were repeated with similar results. (I,J) As described in (G,H),
eans+S.D. from n=3 parallel cultures. Asterisks indicate signiﬁcant differences between
XIAP expression does not result in compensatory regulation of proteins involved TRAIL-
lyzed by Western blotting. The expression of death receptor 4 (DR4) and 5 (DR5), FADD,
ding control.
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isolated lymphocytes to death receptor stimuli [24].
The reduced clonogenicity of XIAP-deﬁcient cells upon TRAIL but
not STS treatment suggests a more prominent role of XIAP in the death
receptor pathway. Death receptor stimulation results in formation of
the death inducing signaling complex (DISC), the activation platform
for initiator caspases-8 and -10. In most cell lines caspase-8 truncates
and thus activates the BH3-only protein Bid. Truncated Bid in turn
inducesMOMP and subsequent effector caspase activation. A few non-
adherent cell lines which are unsuitable for imaging studies however
were shown not to essentially require MOMP to execute apoptosis. In
these so-called type I cells caspases-8/-10 seem capable of directly
activating caspase-3 [59]. Recent systems analyses showed that the
efﬁciency of this link may crucially depend on the expression level of
XIAP and other caspase-3 binding IAPs [32]. Positive feedback from
caspase-3 to caspase-8 could therefore contribute to the increased
susceptibility of XIAP-deﬁcient cells observed upon TRAIL treatment
in this study. Bypassing mitochondria for the initiation of cell death
execution however suggests that activation of caspase-3 could occur
before MOMP. We could not detect any such cells, indicating that this
is either a very rare event or that already minuscule caspase-3
activation directly induces MOMP and therefore cannot be resolved
yet experimentally. Direct caspase-8 caspase-3 signaling does not
seem to play a role in parental XIAP expressing cells as here effector
caspase activation clearly set on minutes after MOMP. Similar delays
were reported before in breast and cervical cancer cells [9,16].
We could show that TRAIL-sensitization of XIAP-deﬁcient cells is
uncoupled from MOMP-induced effector caspase activation. Besides
inhibiting caspases, XIAP can function as a regulator of signaling
pathways that more generally could contribute to cell death resistance
upstream of mitochondrial permeabilisation. XIAP promotes cell
survival by activating MAP kinases such as TAK1 and JNK1, a function
that is synergistically enhanced by the XIAP binding protein ILPIP
[60,61]. XIAP mediated TAK1 activation can activate transcription
factor NF-κB [62,63]. As xiap itself is an NF-κB target gene [64], XIAP
possibly contributes to controlling its own expression level via this
feedback. XIAP-dependent NF-κB signaling has been shown to be
induced following stimulation of various cytokine receptors including
also TRAIL death receptors [65]. It is conceivable that TAK1 activation
contributed to the cell survival advantage of the parental cells. The
molecular mechanism of TAK1 activation was recently identiﬁed as
being mediated by direct interaction of the adaptor protein TAB1 with
the XIAP BIR1 domain. Similar to alleviating XIAP-dependent caspase
inhibition, the XIAP/TAB1 interaction can be disrupted by mitochon-
drial XIAP antagonist Smac [66], inhibiting BIR1-dependent survival
signaling downstream of MOMP.
Taken together, our results provide a comprehensive kinetic and
mechanistic understanding of the consequences of physiological XIAP
expression and XIAP deﬁciency on the signaling dynamics during
MOMP-induced apoptosis execution in the complexity of the living
cellular system.
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